Showing results (1-10 of 113) with videos related to
Sort By:
Pageof 12
British Journal of Clinical Pharmacology|February 18, 2014
Model-based clinical drug development in the past, present and future: a commentaryHolly Kimko, José PinheiroCPT: Pharmacometrics & Systems Pharmacology|September 20, 2017
Improving Realism in Clinical Trial Simulations via Real-World DataHolly Kimko, Kwan LeeFrontiers in Systems Biology|September 29, 2025
Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnershipsCesar Pichardo-Almarza, Holly KimkoFrontiers in Pharmacology|April 27, 2026
A digital twin approach for transforming prescription drug labelingHolly Kimko, Edwin Kimko, Sai Phanindra VenkatapurapuJournal of Clinical Pharmacology|September 13, 2014
Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiativeChaitali Passey, Holly Kimko, Partha Nandy, et al.Expert Opinion on Drug Metabolism & Toxicology|May 29, 2012
Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug developmentApexa Bernard, Holly Kimko, Dinesh Mital, et al.The AAPS Journal|May 21, 2021
Systems Modeling to Quantify Safety Risks in Early Drug Development: Using Bifurcation Analysis and Agent-Based Modeling as ExamplesCarmen Pin, Teresa Collins, Megan Gibbs, et al.Journal of Clinical Pharmacology|November 14, 2024
Meta-Analysis of Exposure-Adverse Event Relationships for Antibody-Drug ConjugatesCheng Wang, Linda Irons, Holly Kimko, et al.Biorxiv : the Preprint Server for Biology|May 10, 2023
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibitionHanwen Wang, Theinmozhi Arulraj, Holly Kimko, et al.NPJ Precision Oncology|June 8, 2023
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibitionHanwen Wang, Theinmozhi Arulraj, Holly Kimko, et al.Pageof 12